Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial

Gastroenterology

Volumn 151, Issue 5, 2016, Pages 902-909

  Gane, Edward J ^a   Kowdley, Kris V ^b   Pound, David ^c   Stedman, Catherine A M ^d   Davis, Mitchell ^e   Etzkorn, Kyle ^f   Gordon, Stuart C ^g   Bernstein, David ^h   Everson, Gregory ⁱ   Rodriguez Torres, Maribel ^j   Tsai, Naoky ^k   Khalid, Omer ^l   Yang, Jenny C ^m   Lu, Sophia ^m   Dvory Sobol, Hadas ^m   Stamm, Luisa M ^m   Brainard, Diana M ^m   McHutchison, John G ^m   Tong, Myron ⁿ   Chung, Raymond T ^o   Beavers, Kimberly ^p   Poulos, John E ^q   Kwo, Paul Y ^r   Nguyen, Mindie H ^s   more..

^a Auckland Clinical Studies   (New Zealand)

^b SWEDISH MEDICAL CENTER   (United States)

^c Indianapolis Gastroenterology Research Foundation   (United States)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e Digestive CARE South Florida Center of Gastroenterology   (United States)

^f Borland Groover Clinic   (United States)

^g HENRY FORD HOSPITAL   (United States)

^h Department of Medicine   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j Fundacion de Investigacion de Diego San Juan   (Puerto Rico)

^k Queen's Medical Center   (United States)

^l Digestive Health Specialists   (United States)

^m GILEAD SCIENCES   (United States)

ⁿ HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL   (United States)

^p MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^q Cumberland Research Associates   (Georgia)

^r INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Clinical Trial; DAA; Direct Acting Antiviral; Non Genotype 1 HCV

Indexed keywords

CREATINE KINASE; HEMOGLOBIN; PEGINTERFERON; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; TRIACYLGLYCEROL LIPASE; VELPATASVIR; VOXILAPREVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; DRUG COMBINATION; FUSED HETEROCYCLIC RINGS; GS-9857; MACROCYCLIC COMPOUND; NS3-4A SERINE PROTEASE, HEPATITIS C VIRUS; SERINE PROTEINASE; SULFONAMIDE; VIRAL PROTEIN;

ABNORMAL LABORATORY RESULT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL OUTCOME; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; HYPERGLYCEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; NEW ZEALAND; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; ADOLESCENT; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; SERINE PROTEASES; SOFOSBUVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84994854365     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.07.038     Document Type: Article

References (21)

1. 1 Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
2. 2 Gower, E., Estes, C., Hindman, S., et al. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol 61:Suppl (2014), S45–S57.
3. 3 Mohd Hanafiah, K., Groeger, J., Flaxman, A.D., et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 (2013), 1333–1342.
4. 4 Asselah, T., Boyer, N., Saadoun, D., et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 36:Suppl 1 (2016), 47–57.
5. 5 Kohli, A., Shaffer, A., Sherman, A., et al. Treatment of hepatitis C: a systematic review. JAMA 312 (2014), 631–640.
6. 6 Cento, V., Chevaliez, S., Perno, C.F., Resistance to direct-acting antiviral agents: clinical utility and significance. Curr Opin HIV AIDS 10 (2015), 381–389.
7. 7 Ampuero, J., Romero-Gómez, M., Reddy, K.R., Review article: HCV genotype 3—the new treatment challenge. Aliment Pharmacol Ther 39 (2014), 686–698.
8. 8 American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV Guidance: recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Published 2015. Accessed July 28, 2015.
9. 9 European Association for Study of Liver, EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 63 (2015), 199–236.
10. 10 Sovaldi (sofosbuvir), US prescribing information. 2013, Gilead Sciences, Foster City, CA http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf Accessed March 17, 2016.
11. 11 Harvoni (ledipasvir-sofosbuvir) tablets, US prescribing information. March 2015, Gilead Sciences, Foster City, CA http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf Accessed March 17, 2016.
12. 12 Lawitz, E., Freilich, B., Link, J., et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat 22 (2015), 1011–1109.
13. 13 Feld, J.J., Jacobson, I.M., Hézode, C., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
14. 14 Foster, G.R., Afdhal, N., Roberts, S.K., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
15. 15 Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
16. 16 Rodriguez-Torres, M., Glass, S., Hill, J., et al. GS-9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat 23 (2016), 614–622.
17. 17 Kohli, A., Kattakuzhy, S., Sidharthan, S., et al. Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, nonrandomized trial. Ann Intern Med 163 (2015), 899–907.
18. 18 Taylor, J., Appleby, T., Barauskas, O., et al. P0899: Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857. J Hepatol, 62, 2015, S681.
19. 19 Kirby, B., Yang, J., Yang, C., et al. P0861: Evaluation of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 in healthy volunteers. J Hepatol, 62, 2015, S663.
20. 20 Gane, E.J., Schwabe, C., Hyland, R.H., et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology 151 (2016), 448–456.e1.
21. 21 Lawitz, E., Poordad, F., Gutierrez, J.A., et al. C-SWIFT: grazoprevir (MK-5172) þ elbasvir (MK-8742) þ sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks (interim results). Hepatology, 60(Suppl 1), 2014 LB-33.